Intracellular retinoid-binding proteins are small, tightly folded, com
pact proteins, which appear to be involved in the delivery of retinoid
s to microsomal metabolic enzymes, among other potential roles. Recent
ly, it has been demonstrated that two of these binding proteins, cellu
lar retinol-binding protein (CRBP) and cellular retinol-binding protei
n type II [CRBP(II)], interact with the same microsomal enzyme but in
different manners, depending on the absence or presence of ligand [Her
r, F.M., & Ong, D.E. (1992) Biochemistry 31, 6748-6755]. The structura
l components of the binding proteins responsible for these differentia
l interactions are presently unknown. In addition, it is not clear how
the ligand is able to gain entry into the solvent-inaccessible interi
or binding cavity. Limited proteolysis of the apo and holo forms of CR
BP and CRBP(II) was used to probe the conformational differences betwe
en the different states of these two proteins in solution. It was foun
d that the apo forms of both proteins were significantly more suscepti
ble to proteolysis, and probably adopted a more open conformation, tha
n the holo forms. The initial cleavage site of endoproteinase Arg-C in
the apo forms occurred at a conserved arginine residue near a possibl
e site of ligand entry. Similar results were obtained by limited prote
olysis of cellular retinoic acid-binding protein and heart fatty acid-
binding protein, indicating that a common ligand-induced conformationa
l change may occur for other members of this family of intracellular b
inding proteins. Additionally, it was found that the relative suscepti
bility of holo-CRBP and holo-CRBP(II) to proteolysis was related to th
eir affinities for ligand, with holo-CRBP, which has a significantly l
ower Kd than that for holo-CRBP(II), being the more resistant to prote
olysis. The results of the limited proteolysis experiments, and the im
plications for protein-protein recognition and a ligand entry mechanis
ms, can be related to the known X-ray structures of CRBP and CRBP(II).